Pfizer, Mylan deal takes a coronavirus hit
Apart from R&D disruption, another casualty of the coronavirus epidemic is dealmaking, or in this case, completing planned mergers. In July 2019, Pfizer — Mylan’s manufacturing partner for its flagship EpiPen — inked a deal to combine its off-patent drug business with the generic drugmaker. The deal, which was initially expected to close mid-2020 will now close in the second half of the year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.